Business
RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulationCombines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidateAll-share transaction in which existing Red Light...
About this update from Red Light Holland Corp
[{"type":"list","items":[{"val":[{"type":"text","content":"Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation","length":256,"tagName":"p"}]},{"val":[{"type":"text","content":"Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"All-share transaction in which existing Red Light shareholders are expected to retain approximately 70% ownership following closing ","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Transaction expected to streamline operations, consolidate teams, and improve capital efficiency ","length":96,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":693,"olType":false},{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that they have entered into a definitive arrangement agreement dated March 10, 2026 (the "Arrangement Agreement") pursuant to which Red Light will acquire Filament's business by way of a statutory plan of arrangement (the "Arrangement" or the "Transaction").","length":537,"tagName":"p"},{"type":"text","content":"Key Transaction Highlights","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Adds GMP-compliant pharmaceutical manufacturing and Filament's Health Canada Level 8 Controlled Substances Dealer's Licence, strengthening Red Light's regulatory and production capabilities with Filament's Vancouver-based laboratory and manufacturing facility","length":275,"tagName":"p"}]},{"val":[{"type":"text","content":"Integrates Filament's 76 issued patents across 15 patent families covering natural psilocybin extraction, purification, standardization, stabilization, and alternative delivery formulations","length":193,"tagName":"p"}]},{"val":[{"type":"text","content":"Incorporates Fila...